Compare AbCellera Biologics Inc (ABCL) vs Mercadolibre Inc (MELI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Mercadolibre Inc — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Mercadolibre Inc trades at $1,793.25 (market cap $91.94B). The key difference: Mercadolibre Inc is far larger — about 39.1× AbCellera Biologics Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, AbCellera Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | MELI | |
|---|---|---|
Market Cap | $2.35B | $91.94B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $2.51K |
52-Week Low | $2.78 | $1.55K |
Enterprise Value | $1.99B | $98.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MercadoLibre (MELI) trades at $1,813.61, up 2.85% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical outlook with robust revenue growth of 49% in Q1 2026 and expanding cash flow generation. Analyst consensus remains strongly positive with a $2,230 price target, though margin compression from aggressive investments presents near-term challenges.
MELI offers significant growth potential as Latin America's e-commerce leader, but faces execution risks from margin pressure and legal investigations. The stock trades at premium valuations (P/E 47.66) requiring sustained high growth to justify current levels. Institutional support remains strong with 71.9% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
